Odonate Therapeutics Stock Forecast, Price & News

-0.11 (-3.47 %)
(As of 05/6/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume921,484 shs
Average Volume3.29 million shs
Market Capitalization$118.13 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for Odonate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ODT
Phone(858) 731-8180
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share


Net Income$-111,820,000.00




Market Cap$118.13 million
Next Earnings Date5/11/2021 (Estimated)
OptionableNot Optionable


See More Headlines
Odonate Therapeutics logo

About Odonate Therapeutics

Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.


Overall MarketRank

1.77 out of 5 stars

Medical Sector

180th out of 2,041 stocks

Pharmaceutical Preparations Industry

76th out of 769 stocks

Analyst Opinion: 3.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

Is Odonate Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Odonate Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ODT, but not buy additional shares or sell existing shares.
View analyst ratings for Odonate Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Odonate Therapeutics?

Wall Street analysts have given Odonate Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Odonate Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,860,000 shares, an increase of 67.6% from the March 31st total of 1,110,000 shares. Based on an average trading volume of 4,120,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 6.2% of the company's shares are sold short.
View Odonate Therapeutics' Short Interest

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Odonate Therapeutics

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics, Inc. (NASDAQ:ODT) released its earnings results on Tuesday, February, 23rd. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.09.
View Odonate Therapeutics' earnings history

How has Odonate Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ODT shares have decreased by 88.2% and is now trading at $3.06.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ODT?

5 equities research analysts have issued twelve-month price objectives for Odonate Therapeutics' shares. Their forecasts range from $4.00 to $50.00. On average, they anticipate Odonate Therapeutics' stock price to reach $19.33 in the next twelve months. This suggests a possible upside of 531.8% from the stock's current price.
View analysts' price targets for Odonate Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Kevin C. Tang, Chairman & Chief Executive Officer
  • Ryan Cole, Senior Vice President-Operations
  • Michael S. Hearne, Chief Financial Officer
  • Thomas Wei, Chief Scientific Officer
  • Steven Pfeiffer, Senior Vice President-Technical Operations

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), The Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and CRISPR Therapeutics (CRSP).

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Who are Odonate Therapeutics' major shareholders?

Odonate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.09%), Virginia Retirement Systems ET AL (0.05%) and First Midwest Bank Trust Division (0.03%). Company insiders that own Odonate Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics

Which institutional investors are selling Odonate Therapeutics stock?

ODT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A..
View insider buying and selling activity for Odonate Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Odonate Therapeutics stock?

ODT stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Virginia Retirement Systems ET AL. Company insiders that have bought Odonate Therapeutics stock in the last two years include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $3.06.

How much money does Odonate Therapeutics make?

Odonate Therapeutics has a market capitalization of $118.13 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis.

How many employees does Odonate Therapeutics have?

Odonate Therapeutics employs 134 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is

Where are Odonate Therapeutics' headquarters?

Odonate Therapeutics is headquartered at 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 731-8180 or via email at [email protected]

This page was last updated on 5/6/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.